ADAG vs. ADCT, IMUX, EYEN, CLNN, SPRO, NERV, AEON, RMTI, VACC, and XLO
Should you be buying Adagene stock or one of its competitors? The main competitors of Adagene include ADC Therapeutics (ADCT), Immunic (IMUX), Eyenovia (EYEN), Clene (CLNN), Spero Therapeutics (SPRO), Minerva Neurosciences (NERV), AEON Biopharma (AEON), Rockwell Medical (RMTI), Vaccitech (VACC), and Xilio Therapeutics (XLO). These companies are all part of the "pharmaceutical preparations" industry.
Adagene vs.
Adagene (NASDAQ:ADAG) and ADC Therapeutics (NYSE:ADCT) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, valuation, risk, institutional ownership, analyst recommendations, media sentiment, community ranking, earnings and profitability.
Adagene has a net margin of 0.00% compared to ADC Therapeutics' net margin of -98.33%. Adagene's return on equity of 0.00% beat ADC Therapeutics' return on equity.
Adagene has higher earnings, but lower revenue than ADC Therapeutics.
Adagene presently has a consensus price target of $5.00, indicating a potential upside of 300.00%. ADC Therapeutics has a consensus price target of $8.20, indicating a potential upside of 914.22%. Given ADC Therapeutics' higher probable upside, analysts plainly believe ADC Therapeutics is more favorable than Adagene.
ADC Therapeutics received 24 more outperform votes than Adagene when rated by MarketBeat users. However, 77.27% of users gave Adagene an outperform vote while only 60.29% of users gave ADC Therapeutics an outperform vote.
9.5% of Adagene shares are owned by institutional investors. Comparatively, 67.3% of ADC Therapeutics shares are owned by institutional investors. 21.2% of Adagene shares are owned by company insiders. Comparatively, 35.4% of ADC Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
In the previous week, ADC Therapeutics had 10 more articles in the media than Adagene. MarketBeat recorded 11 mentions for ADC Therapeutics and 1 mentions for Adagene. ADC Therapeutics' average media sentiment score of 0.32 beat Adagene's score of 0.00 indicating that ADC Therapeutics is being referred to more favorably in the news media.
Adagene has a beta of 0.18, indicating that its stock price is 82% less volatile than the S&P 500. Comparatively, ADC Therapeutics has a beta of 1.01, indicating that its stock price is 1% more volatile than the S&P 500.
Summary
ADC Therapeutics beats Adagene on 9 of the 16 factors compared between the two stocks.
Get Adagene News Delivered to You Automatically
Sign up to receive the latest news and ratings for ADAG and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding ADAG and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
